General use cases
- patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
